ArticleBMC gastroenterology2026
Predictive factors and nomogram for post-endoscopic retrograde cholangiopancreatography pancreatitis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic retrograde cholangiopancreatography (ERCP) is a cornerstone of minimally invasive diagnosis and treatment for pancreaticobiliary diseases. However, post-ERCP pancreatitis (PEP), the most common complication, occurs with a relatively high incidence and can lead to organ failure or even death in severe cases. The effectiveness of existing preventive measures is highly dependent on accurate risk stratification, while empirical clinical judgment lacks consistency, underscoring the urgent need for objective and individualized predictive tools.
objectiveTo identify independent risk factors for PEP and to construct a nomogram prediction model for individualized risk assessment in patients undergoing ERCP.
methodsClinical data from 289 patients who underwent ERCP at Jinzhong First People's Hospital between January 2020 and October 2025 were retrospectively analyzed. Patients were divided into PEP and non-PEP groups according to the consensus diagnostic criteria. Univariate analysis was performed to compare demographic characteristics, clinical factors, procedural details, and laboratory parameters between the two groups. Least absolute shrinkage and selection operator (LASSO) regression was used for feature selection, followed by multivariate logistic regression analysis to identify independent risk factors for PEP. A nomogram prediction model was constructed based on these factors. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA) in the training cohort (n = 202) and validation cohort (n = 87).
resultsThe incidence of PEP in this cohort was 10.73% (31/289). Multivariate logistic regression analysis identified five independent risk factors for PEP: sphincter of Oddi dysfunction, history of pancreatitis, pancreatic duct opacification, difficult cannulation, and guidewire access to the pancreatic duct (≥ 3 times). Elevated total bilirubin (TBil) level was identified as an independent protective factor against PEP. The nomogram incorporating these factors demonstrated excellent predictive performance, with AUC values of 0.922 (95%CI: 0.865-0.980) in the training cohort and 0.915 (95%CI: 0.878-0.951) in the validation cohort. Calibration curves showed good agreement between predicted probabilities and actual observations (Hosmer-Lemeshow test P > 0.05), and DCA confirmed the model's clinical utility across a wide range of threshold probabilities.
conclusionThe nomogram model constructed in this study integrates six easily accessible clinical and operational factors, provides an effective and reliable tool for individualized prediction of PEP risk. This model can assist clinicians in early identification of high-risk patients, facilitating targeted preventive interventions and potentially improving the safety of ERCP procedures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.